Which company develops and produces brigatinib/brigatinib?

Brigatinib/Brigatinib (Brigatinib) was initially developed by the American biopharmaceutical company Ardelyx, and was subsequently developed and commercialized by Takeda Pharmaceutical Company Limited, another world-renowned pharmaceutical company. Headquartered in Japan, Takeda Pharmaceuticals is one of the largest pharmaceutical companies in Asia. It conducts innovative drug research and development on a global scale. It has extensive layout and rich experience in the fields of oncology, rare diseases and neuroscience. Brigatinib is one of Takeda Pharmaceutical’s important strategic drugs in the field of targeted treatment of lung cancer.

Brigatinib was originally discovered and entered early development stages by Ariad Pharmaceuticals, which was later acquired by Takeda Pharmaceuticals in 2017 for billions of dollars. This acquisition enabled Takeda to obtain global rights to brigatinib, and also enabled the drug to successfully complete clinical trials and obtain regulatory approval in multiple countries. In 2017, the US FDA first approved brigatinib for patients with ALK-positive metastatic non-small cell lung cancer who have progressed after previously receiving crizotinib treatment. Since then, with the support of further clinical trial data, the FDA approved it as a first-line treatment for ALK-positive lung cancer in 2020. At the same time, brigatinib has also been approved in many countries such as the European Union, China, and Japan, becoming an important part of global ALK targeted therapy.

As Takeda's core product in the field of lung cancer, brigatinib embodies precision medicine's in-depth understanding of targeted mutation therapy. Its good oral bioavailability, long half-life and broad-spectrum coverage of drug-resistant mutations all illustrate its important role in the treatment ofALK fusion gene-positive NSCLC. It is worth mentioning that Takeda is also advancing research on the combination of brigatinib and other immunotherapy or targeted therapy drugs to expand its indications and optimize efficacy, providing new treatment hope for more lung cancer patients.

Reference materials:https://www.alunbrig.com/